Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,937 total articles
McDonald's remains structurally advantaged: high-margin franchised model, resilient brand, and a digital + delivery mix that sustains comparable sales and margin. I see a clear trade: buy at pullback near $360 with a $420 target and a $320 stop, horizon focused on operational catalysts and seasonal travel demand.
BlackBerry is trading like a high-growth software name despite most of its revenue being tied to automotive and embedded systems - a cyclical end market. Recent partnerships and a growing design-win backlog support upside to the $12s, but stretched valuation (PE ~90s, market cap ~ $5.2B) and rising short activity demand a tight stop. This trade ide…
Rubrik reported a clean Q1 beat and raised fiscal 2027 guidance, but the stock sits below near-term moving averages and carries elevated short interest. This trade idea offers a disciplined swing entry at $78.20, a $92 target into a retest of the 52-week high zone, and a $70 stop to limit downside while letting the company’s revenue and cash-flow c…
Baytex Energy ($4.20) looks set for a mean-reversion leg after a volatile 12 months. Technicals are constructive, short interest has pulled back from earlier peaks, and a midstream infrastructure deal in Pembina improves take-away optionality. This trade targets a move toward the 52-week high with a defined stop to limit downside.
Netgear trades at sub-1x revenue and roughly 1.3x book while executing a shift from low-margin consumer hardware to higher-margin subscription services and enterprise offerings. With a solid balance sheet, resolving legal overhangs, and product cadence (WiFi 7 mesh + SASE/security push), the risk-reward favors a buy for patient, event-driven invest…
Micron is trading near $866 after a pullback from its spring highs, but fundamentals argue for an upgrade: record-level profitability (EPS $44.69), massive free cash flow ($26.17B), and a fortress-like balance sheet (debt/equity ~0.06) create a pathway to shareholder-friendly capital allocation and a multiple re-rating. That said, aggressive greenf…
Fifth Third's acquisition of Comerica creates a top-10 bank with scale, and the near-term earnings hit from merger costs masks a clear path to margin and expense improvement. I view the stock as a tactical long around $57.45 with a mid-term target of $64.00 and a $51.00 stop while monitoring integration execution and credit trends.
Abercrombie & Fitch (ANF) is trading at a valuation that understates its cash-generation ability and capital return plan. With trailing EPS near $11.11, EV/EBITDA ~4.3 and free cash flow of $416M, ANF looks fundamentally cheap. Recent catalysts - Q1 beat, a Hollister-Target collaboration, and a $450M buyback program - support a mid-term swing trade…
Novo Nordisk's shares look poised to continue higher as the company converts injectables momentum into a dominant oral position. Strong prescription share for the oral Wegovy launch, supportive technicals and a reasonable P/E for a market leader create an actionable long trade with clearly defined risk controls.
Dyne Therapeutics is a buy at current levels based on late-stage progress in Duchenne muscular dystrophy (z-rostudirsen), a growing neuromuscular pipeline and a large cash cushion. The trade is speculative and high-risk: the reward hinges on regulatory success and commercialization execution, while free cash flow burn, crowded competition, and mean…
4D Molecular Therapeutics just cleared several execution hurdles: 2-year PRISM Phase 2b data showed strong durability in wet-AMD, Phase 3 is enrolled, and the company has secured non-dilutive capital while locking APAC commercialization through Otsuka. With a market cap near $590M and a cash cushion from an $85M upfront partner payment plus a $200M…
Itochu is likely to use its upcoming IR Day to sharpen capital-allocation messaging. The company has a strong free-cash-flow profile and a history of shareholder returns; a clear commitment to larger buybacks or accelerated returns would re-rate sentiment. This trade targets an entry at $19.50 with a $23.00 target and a $17.00 stop, for a long-term…
UroGen's Zusduri is moving from clinical novelty to commercial staple. Recent reimbursement wins and a sharp revenue ramp ($51M in Q1; +152% YoY) suggest the therapy is being adopted into urology workflows. Given a market cap near $2.01B and elevated short interest, the setup favors a long trade sized for a mid-to-long-term horizon, with clear entr…
Palantir is trading at $136.20 after strong momentum and accelerating commercial adoption. The company sits at the intersection of large-scale data integration, AI orchestration and mission-critical workflows for government and enterprise clients. Fundamentals show positive free cash flow ($2.69B) and high retention metrics cited by analysts; valua…
Tesla is trading at $373.57 with a market cap near $1.40T and stretched multiples, but the macro push to reshore high-value manufacturing combined with early commercial strides in Optimus creates an asymmetric opportunity. This trade targets a re-rating into $460 over the next 180 trading days, with a defined stop at $325 to protect against executi…
Compa Compania de Minas Buenaventura looks undervalued relative to its earnings power and the operational catalysts coming into play. At a current price o…
CAE has traded below its near-term averages while clearing key operational headwinds from 2024 impairments. With recurring training revenue, partnerships (including urban air mobility), and a $7.9B market cap that looks reasonable versus recovery optionality, we upgrade CAE to Strong Buy and lay out a clear entry, stop and target for a long trade o…
Agnico Eagle's strategic expansion in Finland is a multi-year value driver that should gradually lower unit costs and extend mine life. This trade idea takes a long position to capture upside as construction milestones, reserve updates, and higher realized gold prices re-rate the stock. Entry, stop and target defined with a long-term horizon and cl…
Quanterix (QTRX) trades near $3.84 with an enterprise value roughly equal to one year of sales. The hardware and ultra-sensitive biomarker franchise gives the company an asymmetric setup: meaningful upside if clinical and commercial adoption continues, limited near-term downside if a deal or improving sales re-rate multiples. This is a tactical lon…
Dorian LPG (LPG) is benefitting from a structural squeeze in LPG shipping capacity and a spike in spot freight. With a market cap near $1.85B, a conservative balance sheet (debt/equity ~0.49), free cash flow of ~$116M and a forward-looking dividend cadence, the stock still has room to run. Technical momentum and compressed valuation metrics vs. cyc…
UiPath has moved from proof-of-concept losses to positive GAAP operating income while ARR and revenue expansion are starting to reflect real product-market fit for agentic automation. At roughly $6.4B market cap, the stock offers a favorable risk-reward: operational profitability, healthy free cash flow, and a valuation that still leaves upside if …
We recommend a tactical long in iHeartMedia (IHRT) at current levels. The company is cheaply valued by equity market cap ($599M) and sits near the low end of its 52-week range, while H2 ad seasonality, podcast monetization and reported M&A interest create catalysts for a re-rating. Trade plan: enter at $3.95, stop $3.40, target $5.25 over a mid-ter…
Realty Income offers a 5%+ yield, a conservative balance sheet (debt/equity ~0.76), industry-leading occupancy and a clear path to total return through dividend compounding and modest multiple expansion. This trade idea lays out an actionable entry at $65.21, a $75 target in 180 trading days and a $60 stop-loss, with catalysts and risks spelled out…
Arcturus (ARCT) has plunged to its 52-week low after a year of churn. With a market cap under $200M, negative enterprise value and a recently approved self-amplifying mRNA COVID vaccine in Europe, this is a high-risk, high-upside buy-and-hold setup. Entry $5.84, stop $4.80, target $12.00 across a long-term (180 trading days) horizon.
Lumentum (LITE) sold off with the wider AI-tech rotation but the underlying drivers - hyperscaler capex, Nvidia investment and a multi-year silicon photonics cycle - remain intact. At a $61.5B market cap and with clearly visible cash flow growth potential, I upgrade to Buy and enter at current levels with a $1,050 target and $720 stop for a 180-tra…
